0001790300-21-000010.txt : 20210917 0001790300-21-000010.hdr.sgml : 20210917 20210917185157 ACCESSION NUMBER: 0001790300-21-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210722 FILED AS OF DATE: 20210917 DATE AS OF CHANGE: 20210917 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: STANKOVICH THOMAS CENTRAL INDEX KEY: 0001181166 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37897 FILM NUMBER: 211261682 MAIL ADDRESS: STREET 1: 1001 CALLE AMANECER CITY: SAN CLEMENTE STATE: CA ZIP: 92673 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ReShape Lifesciences Inc. CENTRAL INDEX KEY: 0001427570 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1001 CALLE AMANECER CITY: SAN CLEMENTE STATE: CA ZIP: 92673 BUSINESS PHONE: 949-429-6680 MAIL ADDRESS: STREET 1: 1001 CALLE AMANECER CITY: SAN CLEMENTE STATE: CA ZIP: 92673 FORMER COMPANY: FORMER CONFORMED NAME: OBALON THERAPEUTICS INC DATE OF NAME CHANGE: 20080220 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2021-07-22 0 0001427570 ReShape Lifesciences Inc. RSLS 0001181166 STANKOVICH THOMAS 1001 CALLE AMANECER SAN CLEMENTE CA 92673 0 1 0 0 Chief Financial Officer Common Stock, $0.001 par value per share 2021-07-22 4 A 0 282382 0 A 315995 D Common Stock, $0.001 par value per share 2021-07-22 4 A 0 90362 0 A 406357 D Common Stock, $0.001 par value per share 2021-09-10 4 S 0 48366 2.89 D 357991 D These shares will vest and be issued with respect to 123,542 shares on July 22, 2021 and the remaining shares vesting monthly thereafter for 36 months pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan. These shares will vest and be issued monthly over 36 months beginning on July 22, 2021 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan. These shares were sold to cover taxes in connection with the vesting of restricted stock units. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.88 to $2.90, inclusive. The Reporting Person undertakes to provide to ReShape Lifesciences Inc., any security holder of ReShape Lifesciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. /s/Thomas Stankovich 2021-09-17